U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Britain Courts Anthropic Amid US Defense Department Dispute 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
SAN RAMON, Calif., Sept. 06, 2016 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan Rigby, President and Chief Executive Officer, will present at the 18th Annual Rodman & Renshaw Global Investment Conference, being held on September 11-13, 2016 at The Lotte New York Palace Hotel in New York City. During the presentation, Mr. Rigby will provide an overview and update on the company's business.
Date: Monday, September 12, 2016
Time: 2:35 PM ET
Room: Louis
A live audio webcast and archive of the presentation will be available through the Events and Presentations page of the company's corporate website (www.steadymed.com).
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent®, a development stage drug product that combines SteadyMed's PatchPump® technology with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Contacts: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 [email protected] The Ruth Group David Burke (646) 536-7009 [email protected]
